19 studies found for:    M13-796
Show Display Options
Rank Status Study
1 Completed A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery
Condition: Acute Kidney Injury
Interventions: Drug: ABT-719;   Drug: Placebo
2 Active, not recruiting A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
Condition: Moderate Risk of CVD
Interventions: Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
3 Terminated
Has Results
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Bapineuzumab 1.0 m/kg
4 Active, not recruiting GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Condition: Lung Cancer, Non-Small Cell
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic;   Biological: Placebo Control
5 Terminated Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab;   Drug: placebo
6 Active, not recruiting
Has Results
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib;   Biological: Trastuzumab
7 Completed
Has Results
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
Conditions: Non-Small-Cell Lung Carcinoma;   Adenocarcinoma
Interventions: Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: AG-013736 (axitinib)
8 Terminated
Has Results
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
Conditions: Carcinoma, Large Cell;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Squamous Cell;   Carcinoma, Adenosquamous Cell
Interventions: Drug: CP 751,871 (Figitumumab);   Drug: Erlotinib
9 Recruiting An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Condition: Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions: Biological: Nivolumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed
10 Completed Effect of Different Doses of SAR110894D on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Condition: Dementia Alzheimer's Type
Interventions: Drug: SAR110894D;   Drug: placebo
11 Completed
Has Results
Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment
Condition: Atrial Fibrillation
Intervention:
12 Active, not recruiting
Has Results
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Condition: Metastases, Brain
Interventions: Drug: capecitabine;   Drug: lapatinib;   Drug: trastuzumab
13 Recruiting Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
Conditions: Pain;   Advanced Cancer
Interventions: Drug: Sativex®;   Drug: Placebo (GA-0034)
14 Terminated Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Condition: Atrial Fibrillation
Interventions: Drug: Idrabiotaparinux;   Drug: Warfarin;   Drug: Placebo (for idrabiotaparinux);   Drug: Placebo (for warfarin);   Drug: Avidin;   Drug: Placebo (for avidin)
15 Terminated Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab;   Drug: placebo
16 Active, not recruiting EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
17 Completed Rivaroxban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
Condition: Venous Thromboembolism
Interventions: Drug: Rivaroxaban (BAY59-7939);   Drug: Enoxaparin
18 Not yet recruiting Cognitive Behavioral Therapy for Insomnia and Nocturnal Hot Flashes in Menopause
Conditions: Menopause;   Insomnia;   Hot Flashes
Intervention: Behavioral: Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI)
19 Completed
Has Results
Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR
Conditions: Tracheitis;   Tracheobronchitis;   Bronchitis;   Chronic Bronchitis;   Community-Acquired Pneumonia (CAP)
Intervention:

Indicates status has not been verified in more than two years